Video1_One-year real-world experience with mavacamten and its physiologic effects on obstructive hypertrophic cardiomyopathy.mov

<p>Mavacamten is a first-in-class cardiac myosin ATPase inhibitor, approved by the United States Food and Drug Administration for the treatment of hypertrophic cardiomyopathy with obstructive physiology (oHCM). Here, we present the real-world use of mavacamten in 50 patients with oHCM at a ter...

Full description

Saved in:
Bibliographic Details
Main Author: Daniel Seung Kim (19510291) (author)
Other Authors: Emily L. Chu (19510294) (author), Emily E. Keamy-Minor (19510297) (author), Ishan Dhananjay Paranjpe (19510300) (author), Wilson L. Tang (19510303) (author), Jack W. O’Sullivan (19510306) (author), Yaanik B. Desai (19510309) (author), Michael B. Liu (19510312) (author), Elise Munsey (19510315) (author), Kimberly Hecker (19510318) (author), Isabella Cuenco (19510321) (author), Beth Kao (19510324) (author), Ellen Bacolor (19510327) (author), Colleen Bonnett (19510330) (author), Andrea Linder (19510333) (author), Kathleen Lacar (19510336) (author), Nancy Robles (19510339) (author), Cindy Lamendola (19510342) (author), Allysonne Smith (19510345) (author), Joshua W. Knowles (9915362) (author), Marco V. Perez (3097971) (author), Masataka Kawana (19510348) (author), Karim I. Sallam (19510351) (author), Chad S. Weldy (9628603) (author), Matthew T. Wheeler (19510354) (author), Victoria N. Parikh (18415984) (author), Heidi Salisbury (19510357) (author), Euan A. Ashley (145648) (author), the Stanford Center for Inherited Cardiovascular Disease (19510360) (author)
Published: 2024
Subjects:
Tags: Add Tag
No Tags, Be the first to tag this record!